Abstract.
The clinical anti-anginal effectiveness of ranolazine is currently being evaluated. However, the mechanism of its anti-ischaemic action is still unclear. The aim of this work was to establish whether ranolazine exerts functional β-adrenoceptor antagonist activity in the rat cardiovascular system.
Radioligand binding studies were performed in rat hearts and guinea-pig lungs for β1- and β2-adrenoceptor affinity, respectively. Ranolazine had micromolar affinity for both β1- and β2-adrenoceptors (pK i5.8 and 6.3, respectively). Developed tension was measured in isolated rat left atria (electrically driven at 4 Hz) and cumulative concentration/response curves to (±)isoprenaline (0.01–1000 nM) constructed. Ranolazine (0.32–10 µM) surmountably but weakly antagonised isoprenaline-induced positive inotropic responses, with an apparent pA 2 of 5.85 (5.69–6.00) and a slope of –0.74 (–0.70 to –0.77). In bivagotomised, atropinised pithed rats, ranolazine per se evoked marked bradycardia at doses above 10 mg/kg i.v. (maximum variation at 80 mg/kg –125±15 bpm, n=6, P<0.001) by a mechanism apparently unrelated to blockade of β1- or β2-adrenoceptors. Cumulative incremental doses of (±)isoprenaline (0.63 ng/kg to 0.16 mg/kg i.v.) administered to pithed rats induced concomitant depressor and chronotropic responses. Animals received either vehicle (saline 0.9% i.v., n=12), atenolol (0.04–2.5 mg/kg i.v., n=6 per dose), ICI 118551 (0.01–0.63 mg/kg i.v., n=6 or 7 per dose), (±)propranolol (0.01–0.63 mg/kg i.v., n=6 per dose) or ranolazine (2.5–80 mg/kg i.v., n=6 or 7 per dose) 10 min prior to isoprenaline. Ranolazine dose-dependently and competitively antagonised isoprenaline-induced decreases in diastolic arterial pressure (DAP, dose ratio 12.2 with 80 mg/kg ranolazine) and increases in heart rate (HR, dose ratio 20.3 with 80 mg/kg ranolazine).
Collectively, these results demonstrate that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Létienne, R., Vié, B., Puech, A. et al. Evidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system. Naunyn-Schmied Arch Pharmacol 363, 464–471 (2001). https://doi.org/10.1007/s002100000378
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002100000378